“Every single brand-new product we’ve launched is actually doing very well,” he added. Shares of the company were up 1.8 percent on Thursday morning.
Total revenue, however, fell 14 percent in dollar terms to $5.34 billion as well as also core earnings per share, which exclude some items, were down 37 percent to 71 cents, reflecting lower income by divestments as well as also investment behind brand-new drug launches.
Analysts, on average, had forecast earnings of 72 cents on revenue of $5.30 billion, Refinitiv data showed. For the full year, the company kept its financial guidance unchanged.